Avinger, Inc. (AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer (CFO) effective June 25, 2018. Mr. Weinswig will succeed Matt Ferguson, who will be leaving the Company to pursue other opportunities. Mr.  Ferguson will remain a full-time employee of Avinger until August 1, 2018, and continue as a consultant through December 31, 2018, to ensure a smooth transition.

Mr. Weinswig brings extensive strategic and operational financial experience to Avinger, including almost 20 years in financial leadership positions in private and publicly-traded technology companies. Mr. Weinswig previously served as the CFO of Emcore, One Workplace, and Aqua Metals. Earlier in his career, he was International Financial Controller for Coherent, and held senior financial positions at Oclaro. Mr. Weinswig began his career in public accounting at PricewaterhouseCoopers and worked at Morgan Stanley as an Equity Research Analyst. He has held both Certified Public Accountant (CPA) and Chartered Financial Analyst (CFA) designations, and received an MBA from Santa Clara University and a BS in Accounting from Indiana University.

“We are excited to welcome Mark Weinswig to our executive leadership team,” said Jeff Soinski, Avinger’s president and CEO. “Mark’s extensive experience in driving operational and financial improvements is a great fit as we launch our new products, execute against our commercial plan and continue to strengthen our organization.

“We appreciate the many contributions Matt Ferguson has made to Avinger and his critical role in financing the development and commercialization of our Lumivascular technology,” continued Mr. Soinski. “I’m glad that Matt will continue to be involved with the Company through the end of the year on a transitional basis, and wish him all the best in his future endeavors.”

For more information, please visit www.avinger.com.